Japan Generics Drug Market Offers Significant Commercialization Opportunities, Says Kuick Research Report Now Available at MarketPublishers.com
26 Apr 2016 • by Natalie Aster
LONDON – Japan can boast advanced research and development facilities that play an important role in development of the local healthcare infrastructure. The local pharma marketplace is opened for foreign trade and input of drugs is high in this country.
Though the Japan’s pharma market is quite mature, there are still opportunities for growth since generic drugs account for a relative small market share. The local pharma market has inclination towards branded drugs consumption.
In Japan, genetic drugs are often included into a therapeutic regime given presence of universal healthcare system.
This market offers significant opportunities in terms of commercialization. Local as well as overseas players are set 'to take advantage of these opportunities since amendable rules enabling foreign companies to venture in this segment have been developed by local regulators.
This is expected to lead to the intensification of the competition and a further fall of generic drugs prices in the country. Besides, this will lead to the building of a strong supply chain.
New research report “Japan Generics Drug Market Outlook 2020” developed by Kuick Research offers an up-close look at the Japan’s generic drugs marketplace. The study provides a bird’s eye view of this lucrative market. It looks at its features, covers local firms and import trends.
The research study also focuses on super generics. It examines patent protection in Japan and pays special attention to various parameters for branded as well as generic drugs in this country.
The research report highlights generic drugs’ usage and insightfully analyses these marketplace. The study discusses favorable factors and commercialization challenges. It explores the competitive landscape and top companies. Future outlook for this marketplace (through 2020) as well as historical data for this market are on hand in the report, too.
Companies mentioned in this cutting-edge study include: Pfizer, GlaxoSmithKline, Actavis, Nichi-Iko Pharmaceutical, Takeda Pharmaceutical, Nipro Pharma and Towa Pharmaceutical, to name a few.
More new in-demand studies by our market research partner are available at Kuick Research page.